Imetelstat for treatment of myelofibrosis

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. ​
   Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737–740.
   Google Scholar
• Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:915–925.
   Google Scholar
• Mascarenhas J, Concise A. Update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S124–S129.
   Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Plos Med. 2006;3:e270.
   Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390.
   Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.
   Google Scholar
• Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127:1317–1324.
   Google Scholar
• Araki M, Yang Y, Masubuchi N, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127:1307–1316.
   Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–1477.
   Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–1708.
   Google Scholar
• Kröger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125:3347–3350. quiz 64.
   Google Scholar
• Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124:1183–1191.
   Google Scholar
• Henson JD, Neumann AA, Yeager TR, et al. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598–610.
   Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
   Google Scholar
• Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121:4832–4837.
   Google Scholar
• Marti-Carvajal AJ, Anand V, Sola I. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev. 2015;CD010298. ​
   Google Scholar
• Mascarenhas J. Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol. 2014;27:197–208.
   Google Scholar
• Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A. 1988;85:6622–6626.
   Google Scholar
• Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503–514.
   Google Scholar
• Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol: CB. 2003;13:1549–1556.
   Google Scholar
• Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521–529.
   Google Scholar
• Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402:551–555.
   Google Scholar
• Lansdorp PM. Telomeres, stem cells, and hematology. Blood. 2008;111:1759–1766.
   Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015.
   Google Scholar
• Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005;102:8222–8227.
   Google Scholar
• Park JI, Venteicher AS, Hong JY, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460:66–72.
   Google Scholar
• Ghosh A, Saginc G, Leow SC, et al. Telomerase directly regulates NF-kappaB-dependent transcription. Nat Cell Biol. 2012;14:1270–1281.
   Google Scholar
• Nitta E, Yamashita M, Hosokawa K, et al. Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism. Blood. 2011;117:4169–4180.
   Google Scholar
• Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere’s length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res. 2011;35:459–464.
   Google Scholar
• Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63:3931–3939.
   Google Scholar
• Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3ʹ–>P5ʹ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005;24:5262–5268.
   Google Scholar
• Frink RE, Peyton M, Schiller JH, et al. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget. 2016. ​
   Google Scholar
• Tefferi A, Al-Kali A, Begna KH, et al. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J. 2016;6:e405.
   Google Scholar
• Bernard L, Belisle C, Mollica L, et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia. 2009;23:287–291.
   Google Scholar
• Ruella M, Salmoiraghi S, Risso A, et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol. 2013;41:627–634.
   Google Scholar
• Brunold C, Braschler TR, Go N, et al. Imetelstat, a potent telomerase inhibitor, inhibits the spontaneous growth of CFU-meg in vitro from essential thrombocythemia patients but not from healthy individuals. Blood. 2011;118:3843.
   Google Scholar
• Iancu-Rubin C, Mosoyan G, Parker CC, et al. Imetelstat (GRN163L), a telomerase inhibitor selectively affects malignant megakaryopoiesis in myeloproliferative neoplasms (MPN). Blood. 2014;124:4582. ​
   Google Scholar
• Bruedigam C, Bagger FO, Heidel FH, et al. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 2014;15:775–790.
   Google Scholar
• Wang X, Hu CS, Li Y, et al. Effects of imetelstat on CD34+ cells of patients with myelofibrosis. Blood. 2014;124:1879.
   Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–928.
   Google Scholar
• Oppliger Leibundgut E, Haubitz M, Burington B, et al. Dynamics of mutations in patients with ET treated with imetelstat. Blood. 2015;126:57.
   Google Scholar
• Tefferi A, Al-Kali A, Begna KH, et al. Telomerase inhibitor imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood. 2015;126:55.
   Google Scholar
• Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373:908–919.
   Google Scholar
• Burdick AD, Sciabola S, Mantena SR, et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid–modified antisense oligonucleotides. Nucleic Acids Res. 2014;42:4882–4891.
   Google Scholar
• Zhao X, Tian X, Kajigaya S, et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016 Nov;175(3):427–439.
   Google Scholar